Drug Interactions between digoxin and Paxlovid
This report displays the potential drug interactions for the following 2 drugs:
- digoxin
- Paxlovid (nirmatrelvir/ritonavir)
Interactions between your drugs
digoxin ritonavir
Applies to: digoxin and Paxlovid (nirmatrelvir / ritonavir)
MONITOR: Coadministration with ritonavir may increase serum digoxin concentrations and the risk of digoxin toxicity. The proposed mechanism is reduced clearance of digoxin due to ritonavir inhibition of p-glycoprotein-mediated renal tubular secretion. In 12 healthy volunteers, pretreatment with ritonavir (300 mg orally twice daily) for 3 days increased the area under the plasma concentration-time curve (AUC) and volume of distribution of digoxin (0.5 mg single IV dose) by 86% and 77%, respectively, compared to placebo. Nonrenal and renal digoxin clearance decreased by 48% and 35%, respectively, while plasma terminal half-life increased by 156%. In an isolated case report, a 61-year-old woman on a stable regimen of digoxin (0.25 mg/day), warfarin, aerosolized pentamidine, lamivudine, stavudine, and indinavir developed digoxin toxicity (7.2 nmol/L) 3 days after ritonavir 200 mg twice a day was added to her regimen. The patient experienced nausea and vomiting, and digoxin was permanently discontinued without sequelae.
MANAGEMENT: Caution is advised if digoxin must be used in combination with ritonavir. Pharmacologic response and serum digoxin levels should be monitored more closely whenever ritonavir is added to or withdrawn from therapy, and the digoxin dosage adjusted as necessary. Patients should be advised to notify their physician if they experience potential signs and symptoms of digoxin toxicity such as nausea, anorexia, visual disturbances, slow pulse, or irregular heartbeats.
References (3)
- Kurata Y, Ieiri I, Kimura M, et al. (2002) "Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein." Clin Pharmacol Ther, 72, p. 209-19
- Phillips EJ, Rachlis AR, Ito S (2003) "Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein?" AIDS, 17, p. 1577-8
- Ding R, Tayrouz Y, Riedel KD, et al. (2004) "Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers." Clin Pharmacol Ther, 76, p. 73-84
Drug and food interactions
ritonavir food
Applies to: Paxlovid (nirmatrelvir / ritonavir)
ADJUST DOSING INTERVAL: Administration with food may modestly affect the bioavailability of ritonavir from the various available formulations. When the oral solution was given under nonfasting conditions, peak ritonavir concentrations decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of the oral solution (within one hour of dosing) with 240 mL of chocolate milk or a nutritional supplement (Advera or Ensure) did not significantly affect the extent and rate of ritonavir absorption. When a single 100 mg dose of the tablet was administered with a high-fat meal (907 kcal; 52% fat, 15% protein, 33% carbohydrates), approximately 20% decreases in mean peak concentration (Cmax) and systemic exposure (AUC) were observed relative to administration after fasting. Similar decreases in Cmax and AUC were reported when the tablet was administered with a moderate-fat meal. In contrast, the extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% carbohydrate) relative to fasting.
MANAGEMENT: Ritonavir should be taken with meals to enhance gastrointestinal tolerability.
References (1)
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
digoxin food
Applies to: digoxin
Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.
Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.
References (2)
- Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
- Becquemont L, Verstuyft C, Kerb R, et al. (2001) "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther, 70, p. 311-6
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.